Cellyan FY26 net loss widens to $1.14 million; revenue falls 34% to $13.43 million
Reuters2026/08/07 20:32- Cellyan Biotechnology posted a net loss of $1.14 million, widening from a net loss of $27,056.
- Revenue fell 34% to $13.43 million, driven by a 39% drop in Supply Chain Services to $7.56 million.
- Procurement and Distribution revenue slid 22% to $5.87 million on intensified competition and exits from low-margin, slow-paying customers.
- Gross profit dropped 43% to $1.39 million, cutting gross margin by 2 percentage points to 10% as pricing was lowered to stay competitive.
- Cash and cash equivalents totaled $221,841, with $9.11 million in working capital; the company also cited $1.4 million in fund-disposal proceeds received by June 30, 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Gurman predicts iPhone Duo: The first foldable may set industry standards, Apple (AAPL.US) foldable could trigger a decade-long upgrade cycle
Renowned financial journalist Mark Gurman stated that Apple’s first foldable iPhone has the potential to elevate the still-experimental foldable phone category to an industry standard. He noted that this device, called the iPhone Duo, is one of Apple’s most influential products, ranking just behind the iMac, iPod, iPad, and Apple Watch.
Element Fleet drops bid for FleetPartners, exits sale process
Anchoring to Nasdaq! Anthropic races toward a record-breaking IPO with fundraising scale targeting SpaceX
Sources indicate that Anthropic PBC has chosen Nasdaq as its listing venue, and the potential IPO is expected to set a historic record.
10-Yr Benchmark Govt Yields - U.S. vs Other Nations
Crypto prices
More
